5 news items
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
ALGS
7 May 24
-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
ALGS
25 Apr 24
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
ALGS
3 Apr 24
statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
ALGS
27 Mar 24
Statement This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
ALGS
5 Mar 24
of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward
- Prev
- 1
- Next